Loratadine Sales Keep Perrigo On Track To Meet Core Business Growth Goals
This article was originally published in The Tan Sheet
Executive Summary
Perrigo expects to meet its fiscal 2004 target for core business growth despite continued delays in the approval of its 10 mg loratadine tablets (Schering-Plough's Claritin)
You may also be interested in...
Leiner Looks To Rule Claritin Equivalent Market With Summer Launches
Leiner Health Products will seek to control the store brand loratadine market with late summer launches of equivalents to Schering-Plough's Claritin RediTabs and D-24
Leiner Looks To Rule Claritin Equivalent Market With Summer Launches
Leiner Health Products will seek to control the store brand loratadine market with late summer launches of equivalents to Schering-Plough's Claritin RediTabs and D-24
Leiner Looks To Rule Claritin Equivalent Market With Summer Launches
Leiner Health Products will seek to control the store brand loratadine market with late summer launches of equivalents to Schering-Plough's Claritin RediTabs and D-24